Literature DB >> 3318361

Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions.

I F Godsland1, V Wynn, D Crook, N E Miller.   

Abstract

We review the hypothesis that the incidence of coronary heart disease (CHD) is higher in men than in women due to differences in plasma lipoprotein risk factors between the sexes. Men and women appear to be equally susceptible to the effects of lipoprotein risk factors for CHD, and the difference between the sexes in lipoprotein risk factors for CHD appears to be consistent with their being, at least in part, responsible for the sex difference in CHD. This is apparent both when men and women of equal age are compared, and when age-related variations in the sex differences in plasma lipoproteins and CHD are considered. Differences between the sexes in lipoprotein concentrations are still present when sex differences in adiposity, cigarette smoking, physical activity, and diet are taken into account. Evidence relating these sex differences in CHD and lipoproteins to the effects of sex hormones is critically examined. It is commonly accepted that androgens induce changes in lipoprotein concentrations that would predispose towards CHD, whereas estrogens are held to have opposite effects. However, much of the evidence for this comes from studies of changes associated with administration of synthetic gonadal steroids or with changes in gonadal function. Studies of differences in lipoprotein metabolism in normal men and women are extremely limited. In males high-density lipoprotein (HDL) cholesterol levels fall at puberty, correlating with the rise in plasma testosterone concentrations. In females, HDL levels do not change at puberty, despite the rise in estrogen concentrations. Evidence for lipoprotein changes during the menopause, when estrogen levels decline, is equivocal. Similarly, the evidence for an increase in CHD incidence at the menopause is inconclusive. National mortality data indicate that the decreasing sex difference in CHD after 50 years of age is due to a declining rate of increase in men rather than to an acceleration in CHD incidence in women. In men the age-related increase in low-density lipoprotein (LDL) concentrations diminishes beyond 50 years of age, whereas in women the rate of increase remains unchanged. Studies of the effects of gonadectomy are of doubtful relevance in assessing the roles of sex hormones in CHD, and have not been performed with sufficient rigor to provide definitive conclusions.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3318361     DOI: 10.1016/0002-8703(87)90552-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  36 in total

1.  Value of Dundee coronary risk-disk.

Authors:  H Tunstall-Pedoe
Journal:  BMJ       Date:  1992-10-31

2.  Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression.

Authors:  T Caulin-Glaser; C A Watson; R Pardi; J R Bender
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

3.  High-density lipoprotein subfractions in normolipidemic individuals without clinical atherosclerosis lipoprotein subfractions in an adult population.

Authors:  Fabio L Sodré; Vera S Castanho; Lucia N Castilho; Silvia de Barros-Mazon; Eliana C de Faria
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

4.  C-reactive protein as an available biomarker determining mental component of health-related quality of life among individuals with spinal cord injury.

Authors:  Hadis Sabour; Sahar Latifi; Zahra Soltani; Hania Shakeri; Abbas Norouzi Javidan; Seyed-Mohammad Ghodsi; Mohammad Reza Hadian; Seyed-Hassan Emami Razavi
Journal:  J Spinal Cord Med       Date:  2016-02-25       Impact factor: 1.985

Review 5.  Anabolic-androgenic steroid effects on endocrinology and lipid metabolism in athletes.

Authors:  M Alén; P Rahkila
Journal:  Sports Med       Date:  1988-12       Impact factor: 11.136

Review 6.  Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention.

Authors:  L G Spagnoli; A Mauriello; A Orlandi; G Sangiorgi; E Bonanno
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 7.  Borderline hypercholesterolaemia: when to introduce drugs.

Authors:  D Bhatnagar; P N Durrington
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

Review 8.  Cardiovascular pharmacology of hormone replacement therapy.

Authors:  G M Rosano; G Panina
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

Review 9.  That oestrogen replacement for osteoporosis prevention should no longer be a bone of contention.

Authors:  T G Palferman
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

10.  Endocrine response to intense interval exercise.

Authors:  A B Gray; R D Telford; M J Weidemann
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.